CHRS / Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management more_horizontal

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter more_horizontal

Coherus and Chinese partner Junshi Biosciences announced U.S. FDA approval of Loqtorzi in all lines of treatment for nasopharyngeal carcinoma (NPC). C more_horizontal

Coherus announced it has resubmitted a biologic license application for one of its products. The FDA had previously issued a complete response letter more_horizontal

Coherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udeny more_horizontal

It is about to be deleted from a popular small-cap equity index. As of Monday, Sept. more_horizontal

REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior managemen more_horizontal

The immuno-oncology biotech specialist delivered stronger-than-expected revenue and earnings in Q2. Coherus also reiterated its full-year guidance and more_horizontal